SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD.

Shanghai Shyndec Pharmaceutical Co., Ltd.

600420

CNE000001JG2

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2025-01-10			5-day change	1st Jan Change
11.02 ^CNY	-0.72%		-4.75%	-7.71%

Jan. 08	Shyndec Pharma Gets China Pharmaceutical Ingredient Approval for Anaesthesia Supplementary Drug	MT
Jan. 03	Chinese Drug Regulator Denies Marketing of Shyndec Pharmaceutical's UTI Treatment Drug	MT

Shyndec Pharmaceutical Unit Gets Nod to Register Cefpodoxime Proxetil Tablets

December 12, 2024 at 12:44 am EST

This article is reserved for members

Already a member?

Not a member ?

Free registration

Latest news about Shanghai Shyndec Pharmaceutical Co., Ltd.

Shyndec Pharma Gets China Pharmaceutical Ingredient Approval for Anaesthesia Supplementary Drug	Jan. 08	MT
Chinese Drug Regulator Denies Marketing of Shyndec Pharmaceutical's UTI Treatment Drug	Jan. 03	MT
Shanghai Shyndec Pharmaceutical Co., Ltd.(SHSE:600420) added to Shanghai Stock Exchange Health Care Sector Index	Dec. 17	CI
Shanghai Shyndec Pharmaceutical Unit Gets China Nod for Antibiotic Ingredient	Dec. 17	MT
Shyndec Pharmaceutical Unit Gets Nod to Register Cefpodoxime Proxetil Tablets	Dec. 12	MT
Shyndec Pharma Unit's Codeine Phosphate Included in China's Listing of Chemical Raw Materials	Dec. 05	MT
Shanghai Shyndec Pharmaceutical Gets Drug Registration for Eye Drops	Dec. 03	MT
Shanghai Shyndec Pharmaceutical Passes Drug Evaluation for Calcium Gluconate Injection	Nov. 27	MT
Shanghai Shyndec Pharmaceutical CFO Resigns	Nov. 26	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024	24-10-28	CI
China Approves Shyndec Pharmaceutical's Listing Application for Epilepsy Drug Ingredient	24-09-05	MT
Shyndec Pharmaceutical Gets Nod to Add Specification to Pravastatin Sodium Tablets	24-08-30	MT
Shyndec Pharmaceutical's H1 Profit Soars 108%, Operating Income Slips 8%	24-08-28	MT
Shyndec Pharmaceutical's Chairman, President Resign	24-08-28	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	24-08-27	CI
Shanghai Shyndec Pharmaceutical Antibiotic Drug Passes Drug Consistency Evaluation	24-08-12	MT
Shanghai Shyndec Pharmaceutical's Chest Pain Drug Passes China's Drug Evaluations	24-07-31	MT
Shyndec Pharmaceutical's Unit Gets Nod to Amend Lipoic Acid Injection's Specification	24-07-19	MT
Shyndec Pharma Unit Gets Rights for Ceftazidime Avibactam Sodium for Injection	24-07-12	MT
Shanghai Shyndec Pharmaceutical Obtains Drug Registration for Anti-Tumor Injection; Shares Jump 9%	24-07-09	MT
Shyndec Pharma Unit Gets China Nod for Analgesic Ingredient	24-06-14	MT
Shyndec Pharma Unit Gets China Nod for Conjunctivitis Eye Drops	24-06-14	MT
China Grants Registration Approval for Shanghai Shyndec Pharmaceutical Unit's Flu Injection	24-05-15	MT
Shanghai Shyndec Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	24-04-29	CI
Shyndec Pharmaceutical's Unit Gets Nod to Market Empagliflozin Tablets	24-04-16	MT

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

Duration

Period

Chart Shanghai Shyndec Pharmaceutical Co., Ltd.

600420: Dynamic Chart

SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products are antibiotics, circulatory system drugs and biological products, including garlic oil soft capsules, lecithin soft capsules and deep-sea fish oil soft capsules. Its bulk pharmaceutical chemicals (BPCs) include macrolide antibiotics, antiviral, anti-tumor, cardiovascular, hormones and weight loss drugs. The Company also offers topical preparations, such as gynecological suppositories and dermatology preparations.

Employees

11,608

Sector

Pharmaceuticals

Calendar

2025-03-27 - Q4 2024 Earnings Release (Projected)

More about the company